Navigation Links
MedImmune Receives U.S. Government Order for Additional 29 Million Doses of Nasal Spray Vaccine for 2009 H1N1 Influenza
Date:9/21/2009

GAITHERSBURG, Md., Sept. 21 /PRNewswire/ -- MedImmune announced today that the U.S. Department of Health and Human Services (HHS) has placed an order for an additional 29 million doses of its live attenuated influenza vaccine (LAIV) against the 2009 H1N1 influenza virus. This brings HHS orders to date to more than 40 million vaccine doses, with a total cumulative contract value of approximately $453 million. Previous HHS orders for approximately 13 million doses of LAIV for the 2009 H1N1 strain were placed in May and July.

The vaccine received approval from the U.S. Food and Drug Administration (FDA) on Sept. 15 and is indicated for the active immunization of individuals 2-49 years of age against influenza caused by pandemic (H1N1) 2009 virus.

MedImmune's development of LAIV for this strain of H1N1 began at the end of April, when the company received the novel virus from the U.S. Centers for Disease Control and Prevention (CDC). Enough bulk vaccine to fill all orders placed by HHS has already been manufactured and about 3.4 million doses have been released by the FDA. Distribution will occur at the direction of public health authorities.

"At MedImmune, our mission is to develop and deliver medicines that change lives, and we are proud that our innovative LAIV technology may help protect the public from the threat of 2009 H1N1 influenza," said Tony Zook, president of MedImmune. "We will continue to work collaboratively with the U.S. government and public health authorities to contribute to the response to this unpredictable infectious disease."

About LAIV

LAIV is different from the injectable influenza vaccine ("flu shot") in that it contains live vaccine virus strains that are weakened so as not to cause the flu. It is delivered into the nose, where the influenza virus usually enters the body, rather than by injection. LAIV prompts the body to begin mounting an immune response after the first dose. MedImmune's influenza vaccines are currently only licensed in the United States.

Important Safety and Eligibility information for Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal

Who may be eligible for Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal?

Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal is a vaccine approved for the prevention influenza disease caused by pandemic (H1N1) 2009 virus in children, adolescents and adults, from 2-49 years of age. Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal may not protect everyone who gets it. This vaccine is for intranasal administration only.

Who may not be able to get Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal?

Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal is not right for everyone. This vaccine must not be given to: people with history of hypersensitivity to eggs, egg proteins, gentamicin, gelatin or arginine; people with life-threatening reactions to previous influenza vaccinations; and children and adolescents receiving aspirin or aspirin-containing therapy. Children less than 24 months of age are not eligible for this vaccine.

The following people may not be able to get Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal or may be able to get it only in certain situations: people with asthma or active wheezing, or children less than 5 years of age with recurrent wheezing; people with a history of Guillain-Barre syndrome; people with a weakened immune system; people with long-term medical conditions including heart disease, kidney disease, and metabolic diseases, such as diabetes; and pregnant women.

If a patient falls into one of these groups, a health care provider will decide if Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal is right for them.

What are the most common side effects of Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal

Most common side effects are based on studies conducted with seasonal trivalent Influenza Vaccine Live, Intranasal manufactured by MedImmune and include runny nose or nasal congestion, sore throat, and fever. For a full list of side effects, please see section 6.1 in the following product information.

For Complete Product Information please visit: http://www.medimmune.com/pdf/products/h1n1_pi.pdf

About MedImmune

MedImmune, the worldwide biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,100 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising candidates, we aim to be the next revolutionary force in biotechnology by delivering life-changing products, industry-leading performance, and a tireless commitment to improving patient health. For more information, visit MedImmune's website at www.medimmune.com.

The Novel Influenza A (H1N1) project has been funded in whole or in part with the Federal funds from HHS/ASPR, under Contract No. HHSO100200900002I. The opinions expressed herein do not represent opinions or statements made or expressed by the U.S. Department of Health and Human Services.


'/>"/>
SOURCE MedImmune
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Catalyst Biosciences Announces Agreement With MedImmune to Discover and Develop Engineered Protease Therapeutics
2. MedImmune Expands Access for Eligible Premature Infants to Receive Synagis(R) at No Cost
3. Medarex to Receive Milestone Payment from MedImmune for Allowance of an Investigational New Drug Application for MEDI-546
4. MedImmune grants 5 new fellowships to help expand premature infant follow-up care research
5. MedImmune Further Expands Autoimmune Disease Research Program Through Collaboration with SBI Biotech
6. MedImmune Prepared to Support Implementation of Expanded ACIP Recommendations for Influenza Vaccinations
7. MedImmune Expands Scientific and Engineering Leadership
8. Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkins Lymphoma Patients
9. MedImmune presents new pharmaco-economic data at AAP regarding infants at high risk for RSV
10. MedImmune to present RSV surveillance and cost-effectiveness data at American Academy of Pediatrics
11. Medimmune announces phase 2 safety data for anti-RSV antibody and national RSV surveillance results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , ... February 12, 2016 ... ... today announced a new initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to develop the advanced ... will recruit top students from U.S. universities who will draw from Siemens’ ...
(Date:2/12/2016)... ... ... Each year, the American Physical Therapy Association (APTA) offers a Combined Sections Meeting. ... Almost 10,000 physical therapists across the country are expected to attend this annual convention ... field and network with their colleagues. As in years past, HydroWorx is proud ...
(Date:2/12/2016)... ... February 12, 2016 , ... The ThedaCare ... San Francisco General Hospital on April 5-7. The series is a multi-day, multi-workshop ... habits. The workshops cover a broad range of topics, including coaching skills, the ...
(Date:2/12/2016)... NC (PRWEB) , ... February 12, 2016 , ... AssureVest ... surrounding areas, is initiating a charity drive that will raise funds earmarked to purchase ... John C. Tayloe Elementary School. , “My school is in a low-income area and ...
(Date:2/12/2016)... ... February 12, 2016 , ... Young Asset ... celebrates the beginning of the latest charity campaign in their community enrichment program. ... Donations to this worthy cause are currently being accepted at: http://artexpressioninc.org/ . ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... LOUISVILLE, Ky. , Feb. 12, 2016 ... it has completed a $47.1 million Series ... investors Cormorant Asset Management, Hillhouse Capital Group ... investors Morningside Venture Investments, AJU IB Investment, ... will be used to further advance clinical ...
(Date:2/11/2016)... , Feb. 11, 2016 Stem cells are ... characterized by self-renewal and the capacity to differentiate into ... new discovery, as the first mouse embryonic stem cells ... not until 1995 that the first culturing of embryonic ... cells were not produced until 2006 As a result ...
(Date:2/11/2016)... , Feb. 11, 2016  Governor Andrew M. Cuomo ... create 1,400 jobs throughout Western New York ... with the SUNY Polytechnic Institute, includes a major expansion ... in Buffalo , as well as ... facility in Dunkirk . The combined ...
Breaking Medicine Technology: